Balagangadhar Totapally, Ariella Barhen, Guillermo De Angulo
{"title":"Hemorrhagic complications and outcomes of children with acute promyelocytic leukemia at initial hospital admission: a multicenter cohort study.","authors":"Balagangadhar Totapally, Ariella Barhen, Guillermo De Angulo","doi":"10.1080/08880018.2025.2506414","DOIUrl":null,"url":null,"abstract":"<p><p>Acute promyelocytic leukemia (APL) is an uncommon subtype of acute myeloid leukemia that is associated with hemorrhagic complications and early death. Our primary objective was to describe the frequency of hemorrhagic complications and outcomes associated with APL during the initial admission using the Pediatric Health Information System (PHIS) database. We performed a retrospective cross-sectional analysis of children with APL not in remission. Demographic characteristics, resource utilization, and outcomes were compared between those with and without hemorrhagic complications. Out of 173 patients with APL, hemorrhagic complications (intracranial, gastrointestinal, or pulmonary) occurred in 32%. Children with hemorrhagic complications were more likely to have acute respiratory failure, coagulopathy, stroke, and cerebral edema. Children with hemorrhagic complications experienced more ICU admissions and mechanical ventilation, and they also received transfusions, low molecular weight heparin, hydroxyurea, and rasburicase more frequently. The median length of stay and mortality rate was not different between the groups. The median length of stay of children who died was significantly lower (<i>p</i> = 0.003) as the majority (78%) who died death occurred within 7 days. Hemorrhagic complications occurred in a 3<sup>rd</sup> of patients with the initial admission of APL, and most deaths occurred during the first week.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"1-11"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2025.2506414","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Acute promyelocytic leukemia (APL) is an uncommon subtype of acute myeloid leukemia that is associated with hemorrhagic complications and early death. Our primary objective was to describe the frequency of hemorrhagic complications and outcomes associated with APL during the initial admission using the Pediatric Health Information System (PHIS) database. We performed a retrospective cross-sectional analysis of children with APL not in remission. Demographic characteristics, resource utilization, and outcomes were compared between those with and without hemorrhagic complications. Out of 173 patients with APL, hemorrhagic complications (intracranial, gastrointestinal, or pulmonary) occurred in 32%. Children with hemorrhagic complications were more likely to have acute respiratory failure, coagulopathy, stroke, and cerebral edema. Children with hemorrhagic complications experienced more ICU admissions and mechanical ventilation, and they also received transfusions, low molecular weight heparin, hydroxyurea, and rasburicase more frequently. The median length of stay and mortality rate was not different between the groups. The median length of stay of children who died was significantly lower (p = 0.003) as the majority (78%) who died death occurred within 7 days. Hemorrhagic complications occurred in a 3rd of patients with the initial admission of APL, and most deaths occurred during the first week.
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.